Immuneering Corporation

About Immuneering Corporation

Immuneering Corporation is a clinical-stage oncology company focused on developing novel drug candidates to help cancer patients outlive their disease. Their mission is to help cancer patients live longer and feel better by outpacing cancer through innovative treatments.

Products & Services

Atebimetinib (IMM-1-104):An oral, once-daily deep cyclic inhibitor of MEK, designed to improve tolerability and expand indications. Currently in a Phase 2a trial for patients with advanced solid tumors, including pancreatic cancer.

Pipeline Drug Candidates:Novel drug candidates designed to modulate cell signaling dynamics, selectively impacting tumor cells while improving tolerability and expanding indications for a broader population of cancer patients.

Specialties

Cancer treatment Drug development Cell signaling dynamics Small molecule drug programs

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 175000000 MR: - FA: $175 million FAN: 175000000	D: 2025-09-25 FD: 2025-09-25	1 investors
2	RT: Underwritten Public Offering and Private Placement T: - FT: Underwritten Public Offering and Private Placement	A: 25000000 MR: - FA: 25.0 million FAN: 25000000	D: 2025-09-24 FD: 2025-09-24	1 investors
3	RT: Private Placement T: - FT: Private Placement	A: 25000000 MR: - FA: approximately $25 million FAN: 25000000	D: 2025-08-26 FD: 2025-08-26	1 investors
4	RT: Private Placement T: - FT: Private Placement	A: 25000000 MR: - FA: approximately $25 million FAN: 25000000	D: 2025-08-21 FD: 2025-08-21	-
5	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 30000000 MR: - FA: 30 million FAN: 30000000	D: 2023-04-18 FD: 2023-04-18	3 investors

Underwritten Public Offering Latest

2025-09-25

$175.0M

1 investor (Pro only)

Underwritten Public Offering and Private Placement 2025-09-24

$25.0M

Private Placement 2025-08-26

$25.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael Bookman

Chief Legal Officer and Secretary

H

Harold "E.B." Brakewood

Chief Business Officer

B

Brett Hall

Chief Scientific Officer

I

Igor Matushansky

Chief Medical Officer

M

Mallory Morales

Chief Accounting Officer, Treasurer

L

Leah Neufeld

Chief People Officer

View 55 more team members with Pro

Unlock Full Team Directory

Recent News